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Dear Editor, 
According to the data from the Edinburgh Type 2 Diabetes Study up to 43% of type 2 diabetes 
mellitus (T2DM) patients have non-alcoholic fatty liver disease (NAFLD) which is associated with 
greater burden of diabetic complications in T2DM population (1). Liver biopsy, the gold standard for 
NAFLD diagnosis is not routinely performed because it is an invasive procedure with a certain degree 
of sampling error (2). Instead, alternative diagnostic methods have been developed and fatty liver 
index (FLI) as a measure of liver fat content that correlates with abdominal ultrasound and is 
calculated using an equation including body mass index (BMI), waist circumference, triglycerides 
(TG) and GGT is one of them (3). Glucagon-like peptide-1 (GLP-1) receptor agonist exenatide is a 
glucose lowering agent who possesses proven efficacy in achieving and maintaining glycaemic 
control, weight loss, and improvement in metabolic parameters (4). The decrease in glycated 
haemoglobin (HbA1c) levels in T2DM patients treated with exenatide was shown to correlate with 
hepatic fat reduction (5). Recent studies reported the presence of GLP-1 receptor on human 
hepatocytes and the possible direct exenatide modulation of intrahepatic lipid metabolism and insulin 
signalling with a consequent improvement in hepatic steatosis (6).  
The aim of our study was to evaluate the effect of exenatide therapy, alone or in combination with oral 
hypoglycaemic agents (OHA), compared to OHA on hepatic fat quantity measured by FLI.  
Out of 125 T2DM patients included in the study, 61 (48.8%) were male, mean age was 57±8 years, 
BMI 38.57±5.35 kg/m2, waist circumference 119.5±14.5 cm, diabetes duration 12±7 years, and 
HbA1c level 8.57±1.49%. Eighty-seven recieved exenatide therapy: exenatide alone 17 (19.5%), 
exenatide and metformin 38 (43.7%), exenatide and sulphonylurea 7 (8%), exenatide and metformin 
and sulphonylurea 25 (28.7%), and 38 metformin or/and sulphonylurea, i.e. metformin 15 (39.5 %), 
sulphonylurea 2 (5.3%), metformin + sulphonylurea 21 (55.3%) patients. Exenatide was used in 
dosage of 10 µg twice daily. All subjects were studied in the morning between 08:00 and 09:30 hours 
after an overnight fast at the study entry and after 6 months. Basic anthropometric measurements were 
performed on all study subjects. Fasting venous blood samples were collected for the determination of 
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complete blood count and biochemistry panel, lipid profile status, HbA1c and liver biochemistry. FLI 
was calculated according to the formula: FLI = (e 
0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist 
circumference - 15.745
) / (1 + e 
0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745
) * 100. 
Glucose, cholesterol and triglycerides in serum were measured by an enzymatic colorimetric method. 
Complete blood count was determined on an automatic blood counter (Advia 120, Siemens Diagnostic 
Solutions, USA). Aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-
glutamyltransferase (GGT) and alkaline phosphatase (ALK) were measured using standard laboratory 
methods.  
The detailed baseline and 6 months after characteristics as well as their changes are given in table 1. 
The exenatide treated group showed significantly higher change in BMI, waist circumference, ALK, 
ALT and FLI while lower HbA1c change after 6 months treatment compared to OHA group.  
In this open label parallel-group uncontrolled 6 months study we assessed changes in NAFLD 
markers, FLI, BMI, waist circumference, HbA1c and TG levels in two T2DM groups of patients, one 
treated with exenatide and the other treated with metformin or/and sulphonylurea. The data from our 
study suggests that the addition of exenatide to current OHA therapy results in reduction of NAFLD 
marker levels and intrahepatic fat quantity calculated by FLI. In both exenatide and OHA group a 
decrease in BMI and HbA1c value was noticed. Similar effect of GLP-1 agonists (exenatide and 
liraglutide) was observed by Cuthnerson et al. (2012) (5). They reported a significant intrahepatic liver 
fat and biomarker reduction followed by 6 months GLP-1 agonists therapy in 25 T2DM patients. Data 
from the study of Klonoffa et al (2008) (7) suggest that exenatide treatment in T2DM patients leads to 
significant ALT and intrahepatic fat reduction in correlation to insulin resistance decreasment. 
Sathyanarayana et al (2011) (9) performed an uncontrolled observational study with exenatide and 
pioglitazone and highlighted the benefit effect of exenatide to intrahepatic fat content independently of 
BMI reduction. This data clearly suggest that exenatide therapy could reduce or even reverse hepatic 
fat accumulation. The question arises whether exenatide has direct effect on intrahepatic liver fat 
reduction or it is mediated by weight loss and improved glucose control. 
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The reduction in hepatic fat content in exenatide group could be partially explained by reduced caloric 
intake which is one of the main therapeutic contributions of this drug (4). That is in concordance with 
decrease in TG levels in the exenatide group and the increase of TG levels in the OHA group. That is 
also consistent with the BMI and waist circumference reduction which was greater in the exenatide 
group. However, patient food intake was not controlled, and both groups did have decrease in BMI as 
well as waist circumference so the effect of reduced caloric intake could be argued.  
There are several studies explaining the molecular pleiotropic effect of exenatide on human 
hepatocytes and the hepatic fat reduction. Although the data from Samson et al (2009) (10) suggest 
that exenatide might reduce hepatic fat increasing adiponectin mediated activation of AMP-activated 
protein kinase and mitochondrial fat oxidation enhancement,  recent studies suggest that a direct effect 
of exenatide on hepatic lipogenesis and lipid oxidation cannot be ruled out. GLP-1 treatment in mice 
resulted in a significant reduction in mRNA expression of stearoyl-CoA desaturase 1 and genes 
associated with fatty acid synthesis (10). Additionally, the presence of GLP-1 receptor on human 
hepatocytes has been confirmed as well as activation of signal transduction cascades that lead to 
decreasment in hepatic steatosis by modulation of insulin signalling pathway after exenatide binding 
(6). Consistent with this, exenatide plays a direct important role in hepatic fat metabolism but the 
responsible molecular mechanism needs further research. 
The present study is limited by the unavailability of performing liver biopsy, the “gold standard” 
procedure for diagnosis of NAFLD. 
In conclusion, introduction of exenatide therapy to T2DM patients seems to have positive pleiotropic 
effect in liver, especially in hepatic fat metabolism, although so far it has been mostly studied for its 
effect in weight reduction, glucose dependent insulin secretion with consequent glucoregulation and 
positive cardiovascular effects. However, whether the detection of decrease in hepatic fat content in 
T2DM patients treated with exenatide is due to GLP-1 based therapy itself or the ∆FLI is mostly due 
to improvement in abdominal fat accumulation needs to be assessed in further follow-up studies. 
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Table 1. The comparison between baseline and 6 months after characteristics as well as their changes 
in the exenatide and OHA group. 
 
Variable   EXENATIDE GROUP (n=87) OHAGROUP (n=38) p 
Age (years)    57±7                      58±10                 NS 
Gender (m/f)   41/46                           20/18                 NS 
Duration of 
diabetes (years)   
10 ±6                      14±6                0.001 
BMI baseline  
(kg/m2) 
  
38.95±5.32                        37.73±5.41                  NS 
BMI  after 6 
months (kg/m2)  
∆ BMI (kg/m2) 
  
35.80±5.56 
 
 -2.76±2.74 
                       35.42±4.42 
 
                             1.21±2.35 
                 NS 
 
                 0.005 
Waist 
circumference 
baseline (cm) 
  
119.93±13.08                        118.58±16.96                     NS 
Waist 
circumference 
after 6 months  
(cm) 
  
109.89±16.64                         119.26±17.47                     NS 
∆ waist 
circumference 
(cm) 
  
-7.47±12.23                            -1.89±5.88                  0.035 
HbA1c  
baseline (%) 
  
8.62±1.47                              8.67±1.52                    NS 
HbA1c  after 6 
months (%) 
  
7.59±1.36                               8.65±1.63                  0.033 
∆ HbA1c  (%)    -0.88±1.46                              -0.19±1.86                      NS                 
Triglycerides 
baseline 
(mmol/L) 
  
2.02 (0.86-10.89)                          2.06(0.92-7.72)                      NS 
Triglycerides 
after 6 months 
(mmol/L) 
  
1.76(0.70-6.32)                        2.08(0.95-4.42)                      NS 
  
9 
∆triglycerides 
(mmol/L) 
  
-0.11(-10.2-2.1)                    -0.14(-3.1-2.3)                      NS 
AST baseline 
(U/L) 
  
24(12-76)                           21(13-61)                      NS 
AST after 6 
months (U/L)   
22(13-61) 24(11-59)                 NS 
∆AST (U/L)   
-3(-42-41)                          -2(-11-34)                     0.05 
ALT baseline 
(U/L)   
34(10-89)                           24(8-72)                    0.015 
ALT after 6 
months (U/L) 
 
  
26(13-88)                       26.5(11-72)                     NS 
∆ALT (U/L)   -4(-50-46)                          0(-37-26)                  0.045 
GGT  
baseline(U/L)   
39.50(12-225)                       28.50(11-149)                    0.027 
GGT after 6 
months (U/L)   
33(12-103)                          31(15-173)                     NS 
∆GGT (U/L)   -6(-126-26)                          0(-34-116)                     NS 
ALP baseline 
 
ALP after 6 
months (U/L) 
 
∆ALP (U/L)   
85(30-139) 
 
76.5(22-172) 
-4(-57-47) 
                         84(39-126) 
 
                           81(15-168)  
                                1(-58-77)                  
                    NS 
 
                 0.041 
                NS 
FLI baseline   39.24±27.57                          31.65±29.64                   NS 
FLI after 6 
months   
19.9±18.65                            30.59±24.83                0.046 
∆FLI   -25.95±23.15                         -11.01±25.48                 0.003 
 
 
